Despite major scientific progress, there are hardly any effective, science-based anti-aging nutraceuticals.
Most longevity supplements are based on outdated ideas of aging, such as the idea that antioxidants slow down aging.
Others contain ingredients that are healthy, but unfortunately don’t extend lifespan.
Some supplements contain one or two ingredients that might extend lifespan, such as nicotinamide riboside (NR), but the jury is still out.
A much better longevity supplement would contain many ingredients that simultaneously work on multiple causes of aging, resulting in synergies that are greater than the sum of their parts.
We at NOVOS believe much more can be done to slow down aging through science, so we create the first supplements in the world that are:
- Based on the best available science
- Created with the world’s top experts in the aging field
- Use scientifically validated ingredients that extend lifespan in various organisms
- Focused on ten or more aging mechanisms to leverage synergistic effects
- Include ingredients shown to have beneficial effects on aging in humans
The result is NOVOS, the best longevity supplements available.
Click here for more information about the science behind NOVOS, including a selection of dozens of representative studies supporting the use of each ingredient in our products.
NOVOS’ Scientific Advisory Board & Consultants – The Best Minds in Longevity Science
NOVOS’ scientific advisors are biochemists, geneticists and professors from Harvard, MIT, University of Liverpool, University of Washington, and other universities around the world.
Our scientists have received honors that include Breakthroughs in Gerontology Award, an Alzheimer’s Association New Investigator Award, and an Ellison Medical Foundation New Scholar in Aging Award.
Each one of them is a pioneer in the longevity field and have been featured by 60 Minutes, TIME magazine, BBC, CNN, Science, Scientific American, Washington Post, New York Times, and countless other publications.
Dr. George Church, PhD
Harvard Medical School & MIT Professor
Dr. George Church published the first direct genomic sequencing method in 1984 and is known as the “father” of synthetic biology and personalized genomics. Dr. Church has received various accolades, which include election to the National Academy of Sciences and the National Academy of Engineering. He is a recipient of the American Society for Microbiology Promega Biotechnology Research Award. His most cited work has been published in peer reviewed scientific journals including PNAS, Nature Genetics, Nature Biotechnology, Science, the Journal of Molecular Biology, Nature, and many others.
Dr. Pamela Maher, PhD
University of British Columbia, Salk Institute for Biological Studies
Dr. Maher worked for 5 years as an assistant professor at the Whittier Institute for Diabetes and Endocrinology in La Jolla, CA, then moved to The Scripps Research Institute in 1994 as an associate professor. In 2004, she moved to her current position at The Salk Institute. Her research interests focus on using natural products such as flavonoids, small molecules that are widely distributed in fruits and vegetables, to maintain nerve cell function in the presence of toxic insults, especially in relation to Alzheimer’s, dementia & Parkinson’s.
Dr. J Pedro de Magalhaes, PhD
Harvard Medical School, University of Liverpool
Dr. de Magalhaes leads the Integrative Genomics of Aging Group at the Institute of Integrative Biology, University of Liverpool, UK. Dr. de Magalhaes completed his postdoc with genomics pioneer, Dr. George Church, at Harvard Medical School. He developed high-throughput approaches for studying aging, including computational tools and databases, statistical models of mortality, and comparative genomics methods for investigating the evolution of longevity. Dr. de Magalhaes maintains several databases related to the impact that drugs & natural substances have on aging.
Dr. Matt Kaeberlein, PhD
Massachusetts Institute of Technology, University of Washington – Consultant
Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. Dr. Kaeberlein’s research interests focus on basic mechanisms of aging in order to identify interventions that promote healthspan and improve quality of life. He has published nearly 200 papers in top scientific journals and has been recognized by prestigious awards, including Breakthroughs in Gerontology, Alzheimer’s Association Young Investigator Award, Ellison Medical Foundation New Scholar in Aging, a Murdock Trust Award, Pioneer in Aging, and Vincent Cristofalo Rising Star in Aging Research.
Dr. Oliver Medvedik, PhD
Harvard Medical School, The Cooper Union
Director of the Kanbar Center for Biomedical Engineering, Cooper Union. Dr. Medvedik has worked as a biotechnology consultant at Sirtris Pharmaceuticals and has taught molecular and synthetic biology while at Harvard University, The Cooper Union, School of Visual Arts, Genspace and NYU. He is also co-founder and vice-president of the non-profit organization LEAF (Life Extension Advocacy Foundation), where he serves on the board of directors. Dr. Medvedik performed his doctoral research at Dr. David Sinclair’s Harvard lab, and is a coauthor on multiple papers including studies on NAD+ and calorie restriction.
Dr. Avi Rosenbaum, PhD
Harvard Medical School
Scientist and Consultant, with deep knowledge of the biotech industry. Experience and international network in Genomics, Personalized Medicine, Gene Therapy and Synthetic Biology. Built the first academic Next Generation Sequencing platform. Launched more than ten commercial products. Investor and mentor in biotech, pharma, medical and food-tech companies. Holder of five patents, and co-author of high-profile academic publications with over 2,500 citations.
Dr. Robert Lufkin, MD
USC School of Medicine
Dr. Lufkin is Chief of Metabolic Imaging at a medical network in California and a distinguished Professor of Radiology at the USC School of Medicine, with over 200 peer-reviewed scientific papers to his credit and 14 books published. Dr. Lufkin has held several prestigious professional affiliations, including the presidency of the Society of Magnetic Resonance Imaging and the American Society of Head and Neck Radiology. He is also the inventor of several patents in artificial intelligence, including the globally-used MR-compatible biopsy needle, the “Lufkin Needle.”
Dr. Diogo Barardo, PhD
National University of Singapore, NOVOS Head of R&D
Diogo Barardo, PhD is a distinguished longevity researcher, machine learning expert, and former Postdoctoral Research Fellow at Professor Brian Kennedy’s renowned Center for Healthy Longevity at the National University of Singapore. Diogo authored the first paper of machine learning on predicting anti-aging compounds. He also created DrugAge, the world’s largest database of longevity-enhancing compounds. Diogo’s work ranges from C. elegans to mice to humans and has been cited in 1,000 research papers.
About NOVOS’ nutraceuticals
- Don’t hide signs of aging, they address the root causes.
- Are based on real science, not anecdote, tradition or belief.
- Address many important mechanisms of aging, not just one or two.
- Use ingredients found in nature and are safe for long-term use.
- Our foundational formulation, NOVOS Core, is a water-soluble powder, enabling full doses and absorption of ingredients, not a pill with a small fraction (if NOVOS Core were a pill, it would require 10+ capsules!).
Technology to track your progress
We are working on providing you with the best tests to track your health and longevity:
- Benefit from state-of-the art tests to get a birds-eye view of your health and longevity status.
- Test how old you really are (your biological age) instead of relying on your chronological age.
- Receive guidance on how to improve your biological age with lifestyle tweaks, beyond the NOVOS formula.
- Keep motivated with regular check-ups and re-testing.
- We achieve this using the best-in-class epigenetic tests, hematological tests, and facial tests, based on superior algorithms and AI.
We fund research to create the best formulations
We’re agnostic to ingredient selection. So we are free to choose the best ingredients proven to improve health span and lifespan. And we fund responsible research in humans, to be confident that our product is the best.
We are a Public Benefit Corporation (PBC)
A portion of our profits and equity is donated to nonprofits in the longevity science space, like the 501(c)(3), Life Extension Advocacy Foundation (LEAF).
We also create free content to educate people on how to live longer, healthier lives, even if they don’t use NOVOS, which you can find here.
NOVOS is founded by longevity activists who are in it for the really, really long term!
The team at NOVOS is fascinated by longevity science and in it for the remainder of their very long lives. The team believes that addressing aging is the best way to keep people healthy, avoiding chronic illnesses of age and looking and feeling their best for the longest time possible.
Founder & CEO
Chris Mirabile graduated from NYU Stern School of Business and later won their business plan competition with his startup company, Hotlist, a location-based social network that scaled to 220 million people’s social plans. Chris has launched multiple successful technology ventures, and has advised biotech startups and NYU Langone Hospital. Chris’ interest in health began when he was 12, and evolved into a passion after he was cured of a brain tumor when he was 16. Chris has researched and integrated longevity practices and interventions into his life for more than ten years, has achieved a biological age 13.6 years younger than his chronological age, and according to epigenetic tests like DunedInPACE, is aging 31% slower biologically than chronologically.
Dr. Kris Verburgh, MD
Kris Verburgh is a medical doctor specialized in aging and longevity. He is a researcher at the University of Brussels and faculty member at Singularity University Benelux where he teaches about the future of medicine and longevity. He is a partner at a $100 million investment fund that invests in new technologies to address aging. He wrote his first science book when he was 16 years old, and by age 28 he had written four science books, including The Longevity Code. Since a young age he has given talks for many organizations and institutions, including European Parliament, Cambridge University, and various Fortune 100 companies.